{"id":"https://openalex.org/W4413783201","doi":"https://doi.org/10.1016/s2152-2650(25)02284-0","title":"ABCL-674: A Phase 1 Trial of NX-2127, a First-in-Class BTK Dual-Targeted Protein Degrader, in Patients With Relapsed/Refractory B-cell Malignancies","display_name":"ABCL-674: A Phase 1 Trial of NX-2127, a First-in-Class BTK Dual-Targeted Protein Degrader, in Patients With Relapsed/Refractory B-cell Malignancies","publication_year":2025,"publication_date":"2025-08-28","ids":{"openalex":"https://openalex.org/W4413783201","doi":"https://doi.org/10.1016/s2152-2650(25)02284-0"},"language":"en","primary_location":{"id":"doi:10.1016/s2152-2650(25)02284-0","doi":"https://doi.org/10.1016/s2152-2650(25)02284-0","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s2152-2650(25)02284-0","pdf_url":null,"source":{"id":"https://openalex.org/S186546955","display_name":"Clinical Lymphoma Myeloma & Leukemia","issn_l":"2152-2650","issn":["2152-2650","2152-2669"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-1","ki-jl-1","medline","norway-1"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Lymphoma Myeloma and Leukemia","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5067633124","display_name":"Alexey Valeryevich Danilov","orcid":"https://orcid.org/0000-0003-4461-0970","observed_orcids":["https://orcid.org/0000-0003-4461-0970"]},"institutions":[{"id":"https://openalex.org/I1301076528","display_name":"City Of Hope National Medical Center","ror":"https://ror.org/00w6g5w60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alexey Danilov","raw_affiliation_strings":["City of Hope National Medical Center, Duarte, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"City of Hope National Medical Center, Duarte, CA, USA","institution_ids":["https://openalex.org/I1301076528"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058757098","display_name":"Michael Timothy Tees","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210134093","display_name":"Colorado Blood Cancer Institute","ror":"https://ror.org/040pncp85","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210134093"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Tees","raw_affiliation_strings":["Colorado Blood Cancer Institute, Denver, CO, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Colorado Blood Cancer Institute, Denver, CO, USA","institution_ids":["https://openalex.org/I4210134093"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011348837","display_name":"Harsh Shah","orcid":"https://orcid.org/0000-0001-6054-5238","observed_orcids":["https://orcid.org/0000-0001-6054-5238"]},"institutions":[{"id":"https://openalex.org/I2801159745","display_name":"Huntsman Cancer Institute","ror":"https://ror.org/03v7tx966","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801159745","https://openalex.org/I4210148268"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Harsh Shah","raw_affiliation_strings":["Huntsman Cancer Institute, Salt Lake City, UT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Huntsman Cancer Institute, Salt Lake City, UT, USA","institution_ids":["https://openalex.org/I2801159745"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073077636","display_name":"Clare Sun","orcid":"https://orcid.org/0000-0001-8498-4729","observed_orcids":["https://orcid.org/0000-0001-8498-4729"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210106489","display_name":"National Heart, Lung, and Blood Institute","ror":"https://ror.org/012pb6c26","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210106489"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Clare Sun","raw_affiliation_strings":["National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210106489"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000959540","display_name":"Ian W. Flinn","orcid":"https://orcid.org/0000-0001-6724-290X","observed_orcids":["https://orcid.org/0000-0001-6724-290X"]},"institutions":[{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ian Flinn","raw_affiliation_strings":["Tennessee Oncology, Nashville, TN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Tennessee Oncology, Nashville, TN, USA","institution_ids":["https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068147019","display_name":"Daniel Arthur Ermann","orcid":"https://orcid.org/0000-0001-9233-294X","observed_orcids":["https://orcid.org/0000-0001-9233-294X"]},"institutions":[{"id":"https://openalex.org/I2801159745","display_name":"Huntsman Cancer Institute","ror":"https://ror.org/03v7tx966","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801159745","https://openalex.org/I4210148268"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel Ermann","raw_affiliation_strings":["Huntsman Cancer Institute, Salt Lake City, UT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Huntsman Cancer Institute, Salt Lake City, UT, USA","institution_ids":["https://openalex.org/I2801159745"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021496101","display_name":"Jason R. Westin","orcid":"https://orcid.org/0000-0002-1824-2337","observed_orcids":["https://orcid.org/0000-0002-1824-2337"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jason Westin","raw_affiliation_strings":["MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033996214","display_name":"Michael J. Thirman","orcid":"https://orcid.org/0000-0001-5154-9499","observed_orcids":["https://orcid.org/0000-0001-5154-9499"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Thirman","raw_affiliation_strings":["University of Chicago, Chicago, IL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Chicago, Chicago, IL, USA","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030290429","display_name":"Melannie Co","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158736","display_name":"Nurix (United States)","ror":"https://ror.org/05k879m03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158736"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Melannie Co","raw_affiliation_strings":["Nurix Therapeutics, Inc., San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nurix Therapeutics, Inc., San Francisco, CA, USA","institution_ids":["https://openalex.org/I4210158736"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051755498","display_name":"Amanda Schwab","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158736","display_name":"Nurix (United States)","ror":"https://ror.org/05k879m03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158736"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amanda Schwab","raw_affiliation_strings":["Nurix Therapeutics, Inc., San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nurix Therapeutics, Inc., San Francisco, CA, USA","institution_ids":["https://openalex.org/I4210158736"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5099001685","display_name":"Carolina Ryklansky","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158736","display_name":"Nurix (United States)","ror":"https://ror.org/05k879m03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158736"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Carolina Ryklansky","raw_affiliation_strings":["Nurix Therapeutics, Inc., San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nurix Therapeutics, Inc., San Francisco, CA, USA","institution_ids":["https://openalex.org/I4210158736"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108812322","display_name":"May Tan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158736","display_name":"Nurix (United States)","ror":"https://ror.org/05k879m03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158736"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"May Tan","raw_affiliation_strings":["Nurix Therapeutics, Inc., San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nurix Therapeutics, Inc., San Francisco, CA, USA","institution_ids":["https://openalex.org/I4210158736"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045559154","display_name":"Erin Meredith","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158736","display_name":"Nurix (United States)","ror":"https://ror.org/05k879m03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158736"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Erin Meredith","raw_affiliation_strings":["Nurix Therapeutics, Inc., San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nurix Therapeutics, Inc., San Francisco, CA, USA","institution_ids":["https://openalex.org/I4210158736"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5030524385","display_name":"Adrian U. Wiestner","orcid":"https://orcid.org/0000-0002-3533-2924","observed_orcids":["https://orcid.org/0000-0002-3533-2924"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210106489","display_name":"National Heart, Lung, and Blood Institute","ror":"https://ror.org/012pb6c26","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210106489"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Adrian Wiestner","raw_affiliation_strings":["National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210106489"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":9,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3890,"currency":"USD","value_usd":3890},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.22317046,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"25","issue":null,"first_page":"S749","last_page":"S749"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.9243000149726868,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.9243000149726868,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.06960000097751617,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.003599999938160181,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/btk-degraders","display_name":"BTK degraders","score":0.7250000238418579},{"id":"https://openalex.org/keywords/btk-inhibitor-resistance","display_name":"BTK inhibitor resistance","score":0.6349999904632568},{"id":"https://openalex.org/keywords/ikzf1","display_name":"IKZF1","score":0.8209999799728394},{"id":"https://openalex.org/keywords/ikzf3","display_name":"IKZF3","score":0.9919999837875366},{"id":"https://openalex.org/keywords/b-cell-malignancies","display_name":"B-cell malignancies","score":0.746999979019165},{"id":"https://openalex.org/keywords/relapsed-refractory-lymphoma","display_name":"relapsed/refractory lymphoma","score":0.8889999985694885},{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.796999990940094},{"id":"https://openalex.org/keywords/mantle-cell-lymphoma","display_name":"mantle cell lymphoma","score":0.7549999952316284},{"id":"https://openalex.org/keywords/diffuse-large-b-cell-lymphoma","display_name":"diffuse large B-cell lymphoma","score":0.8009999990463257},{"id":"https://openalex.org/keywords/waldenstrom-macroglobulinemia","display_name":"Waldenstr\u00f6m macroglobulinemia","score":0.9120000004768372},{"id":"https://openalex.org/keywords/primary-central-nervous-system-lymphoma","display_name":"primary central nervous system lymphoma","score":0.8360000252723694},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.746999979019165},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.7260000109672546},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.7400000095367432},{"id":"https://openalex.org/keywords/tumor-immune-microenvironment","display_name":"tumor immune microenvironment","score":0.6290000081062317}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8700523376464844},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.6569957733154297},{"id":"https://openalex.org/C90059517","wikidata":"https://www.wikidata.org/wiki/Q423572","display_name":"Bruton's tyrosine kinase","level":4,"score":0.5567451119422913},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5080368518829346},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.45032113790512085},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4384327232837677},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.08595478534698486},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.08130055665969849},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.05506405234336853},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/s2152-2650(25)02284-0","doi":"https://doi.org/10.1016/s2152-2650(25)02284-0","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s2152-2650(25)02284-0","pdf_url":null,"source":{"id":"https://openalex.org/S186546955","display_name":"Clinical Lymphoma Myeloma & Leukemia","issn_l":"2152-2650","issn":["2152-2650","2152-2669"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-1","ki-jl-1","medline","norway-1"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Lymphoma Myeloma and Leukemia","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","score":0.47999998927116394,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2054526083","https://openalex.org/W292197667","https://openalex.org/W1982722523","https://openalex.org/W92473125","https://openalex.org/W1606809499","https://openalex.org/W1569214216","https://openalex.org/W4380029480","https://openalex.org/W93592991","https://openalex.org/W939072932","https://openalex.org/W4280585341"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2025-10-10T00:00:00"}